All In Biotech

Drug Trial Radar · NCT07276282

Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction

Effects of Ziltivekimab Versus Placebo on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction. A Serial, Multivessel, Intravascular Ultrasound, Near-infrared Spectroscopy and Optical Coherence Tomography Imaging Study

Last checked: Nov 19, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 332 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

332

Planned (sponsor's estimate)

Start

Dec 19, 2025

Primary completion

Sep 1, 2028

Study completion Dec 1, 2028

Sponsor

Lead sponsor
ECRI bvIndustry
Sponsor type
Industry
Collaborators
Novo Nordisk A/S; Insel Gruppe AG, University Hospital Bern; Cardialysis B.V.
First posted
Dec 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Despite improvements in the treatment, coronary artery disease (CAD) remains one of the leading causes of death worldwide. Around 20% of people who have suffered a heart attack (myocardial infarction) need to be hospitalized again within a year, and 10% experience another heart attack. Despite currently available medication, patients remain at risk of further episodes after a heart attack. Scientists have discovered that inflammation in the body plays a decisive role in the development and narrowing of arterial blockages (atherosclerosis). This study aims to investigate whether a new treatment that reduces inflammation can help improve the arteries of patients with CAD. This study will examine whether blocking certain inflammation-related substances with a new medicinal product called ziltivekimab affects the buildup and composition of plaques (fatty deposits) in the coronary arteries. Special imaging diagnostic techniques will be used to look inside the arteries and check whether the treatment helps reduce the narrowing caused by dangerous plaques, which can lead to future heart attacks. This is a clinical study in which participants are randomly divided into two groups (randomization): one group will receive the new treatment ziltivekimab and other group will receive a placebo (a harmless substance with no active ingredients). Both groups will continue to receive standard treatment for heart attacks. The study lasts approximately 15 months per participant. The full scientific title of the trial is: Effects of ziltivekimab versus placebo on coronary atherosclerosis in patients with acute myocardial infarction. A study with serial multi-vessel imaging obtained using intravascular ultrasound, near-infrared spectroscopy, and optical coherence tomography techniques.

Conditions

  • Coronary Artery Disease
  • Acute Myocardial Infarction (AMI)
  • Coronary Atherosclerosis of Native Coronary Artery

Interventions

  • ZiltivekimabDrug

    Ziltivekimab is administered subcutaneously (i.e., under the skin) once per month added to standard of care.

  • PlaceboDrug

    Placebo is administered subcutaneously (i.e., under the skin) once per month added to standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in percent atheroma volumeTime frame: From randomization (week 0) to end-of-study (52-week)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bern University Hospital, Inselspital Bern

    Bern, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.